The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-Germany decides AstraZeneca COVID shot can be used for over-60s - document

Tue, 30th Mar 2021 11:19

* Health minister agree AZ can be used for over 60s

* Can also be used for high-risk patients aged below 60

* Several German states to stop giving the shot to under 60s

* PEI registers 31 cases of rare brain blood disorder

* Germany has administered 2.7 mln doses of AZ shot
(Recasts with health ministers' agreement)

By Patricia Weiss and Caroline Copley

BERLIN, March 30 (Reuters) - German federal and state health
ministries agreed that from Wednesday AstraZeneca's
COVID-19 vaccine can be used for people aged 60 and above,
following further reports of a rare brain blood disorder, a
document on their agreement showed.

Acting on advice from Germany's vaccine committee, known as
STIKO, the ministries also agreed the Anglo-Swedish firm's
vaccine could be used for high-risk patients aged below 60 as
well as for high-priority groups such as medical workers.

People aged below 60 who have already received a first
AstraZeneca shot have the option of either receiving their
second shot as planned, if they are high priority, or to wait
for STIKO to issue its recommendation, which it is expected to
do by the end of April.

Earlier, STIKO recommended the shot only be used for people
aged 60 and above "on the basis of available data on the
occurrence of rare but very severe thromboembolic side-effects".

STIKO is also looking into the possibility of administering
a second shot with a different COVID vaccine, the document
showed.

In a statement responding to the STIKO recommendation,
AstraZeneca said patient safety was its highest priority and
noted the European and UK medical agencies had not been able to
establish a causal relationship between the shot and clotting.

"We will continue to work with German authorities to address
any questions they may have," it added.

The meeting of Germany's federal and state health ministries
followed further reports by Germany's vaccine regulator, the
Paul Ehrlich Institute (PEI), of cases of blood clots known as
cerebral sinus vein thrombosis (CSVT).

PEI said it had registered 31 cases of CSVT, which resulted
in nine deaths, out of some 2.7 million people who have received
the AstraZeneca vaccine. With the exception of two cases, all
reports involved women aged between 20 and 63.

Before STIKO issued its statement, several German states,
including Berlin and Brandenburg, as well as the city of Munich,
said they would stop giving the shot to people under 60.

State hospital groups Charite and Vivantes suspended
vaccinations in female staff aged under 55, citing further cases
of CSVT.

Because use of the vaccine in Germany was initially limited
to those under 65, the shot has been administered among younger
women, particularly medical staff and teachers.

Many European countries briefly stopped using AstraZeneca's
vaccine earlier this month while investigating rare cases of
blood clots.

Both the European Medicines Agency (EMA) and the World
Health Organization said this month the benefits of
AstraZeneca's vaccine outweighed the risks.

An EMA review covering 20 million people who took the
AstraZeneca shot in Britain and the European Economic Area found
seven cases of blood clots in multiple blood vessels and 18
cases of CVST.

Millions of doses of the AstraZeneca vaccine have been
safely administered around the world.

Nearly all countries have since resumed use of the vaccine.
But France broke with guidance from the EMA and said on March 19
it should only be given to people aged 55 or older. France said
the decision was based on evidence that the clotting affected
younger people.

Canadian health officials said on Monday they would stop
offering AstraZeneca's shot to people under 55 and require a new
analysis of the shot's benefits and risks based on age and
gender.

Bavarian Premier Markus Soeder criticised the "back and
forth" around the vaccine, saying all recommendations showed
that the danger of severe illness from the coronavirus
outweighed any side-effects linked to the shot.
(Additional reporting by Paul Carrel, Andreas Rinke and Ludwig
Burger; Editing by Nick Macfie and Jonathan Oatis)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.